Email this article Role of metformin pregravid preparation patients with prediabetes impaired glucose toletance
- Authors: Komarov E.K.1, Pluzhnikova T.A.2
-
Affiliations:
- D. O. Ott Research Institute of Obstetrics and Gynecology, RAMS
- SPbSBI “Maternity hoshital N 1”
- Issue: Vol 64, No 3 (2015)
- Pages: 18-25
- Section: Articles
- URL: https://ogarev-online.ru/jowd/article/view/1247
- DOI: https://doi.org/10.17816/JOWD64318-25
- ID: 1247
Cite item
Full Text
Abstract
Tasks of investigation were concluded the characterization of insulin resistence (IR) and hormonal features in patients with prediabetes and influence of diet or metformin on the course of pregnancy and perinatal complications. There were examined 61 womans. The OGTT, definition of insulin levels in plasma and index IR were performed in all patiens. OGTT and index IR were normal in 14 womans (control group I). OGTT was normal but index IR was impared in 33 womans (group IR - II). From this group 22 womans were treated with diet (II A group) and 11 womans treated with metformin (IIB group). OGTT and index IR were abnormal in 14 womans (impared OGTT - III group), they were treated with metformin. Dose of metformin was 1500 mg/d, threatment was continueted for 3-4 manths. Conclusion: Used indexes IR basal and two hour after glucose load were significant in definition of normal and decreased insulin sensitivity (IR). Presence of IR is accompanied by high level of free testosterone in blood without impared secretion of ovarian and suprarenal androgens. There was impared sensitivity of endometrium of secretory stage. The frequency of obstetric and perinatal complications in patients receiving diet not differ from patients treated with metformin. There was only a tendercy to low frequency of threatening miscarriages befor 12 weeks of gestations in paitiens receiving metformin. Development of GDM was observed in 13,1 % of patiens only with presence of IR. The use of metformin in pregravidal stage preserved the development of macrosomia in offsprings of patients with prediabetes.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Evgeniy Konstantinovich Komarov
D. O. Ott Research Institute of Obstetrics and Gynecology, RAMS
Email: iagmail@ott.ru
Ph.D., senior staff scientist
Tamara Aleksandrovna Pluzhnikova
SPbSBI “Maternity hoshital N 1”
Email: plutam@mail.ru
chief of “Center of prophylaxis and treatment of miscarriage”
References
- Балаболкин М. И. Инсулинорезистентность и ее значение в патогенезе нарушений углеводного обмена и сахарного диабета типа 2. Сахарный диабет. 2002; 1: 12-20.
- Болотская Л. Л., Есаян Р. М., Олейнин О. В. 6-й Международный симпозиум “Диабет и беременность”, 23-26 марта 2011 г., Зальцбург, Австрия. Сахарный диабет. 2011; 2: 131-2.
- Виноградова О. К. Противоречия и консенсусы метаболического синдрома. По материалам IV Международного конгресса «Предиабет и метаболический синдром». 6-9 апреля 2011 г., Мадрид. Сахарный диабет. 2011; 2: 127-30.
- Дедов И. И., Краснопольский В. И., Сухих Г. Т. Проект Российского консенсуса «Гестационный сахарный диабет: диагностика, лечение, послеродовое наблюдение».Сахарный диабет. 2012; 2: 6-12.
- Комаров Е. К., Михнина Е. А., Великанова Л. И. Роль инсулинорезистентности в патогенезе гиперандрогенемии у женщин с нарушением репродуктивной функции. Проблемы репродукции. 2005; 5: 25-30.
- Мкртумян А. М., Маркова Т. Н., Кичигин В. А. Эффективность метформина при абдоминальном ожирении. Терапевтический архив. 2014; 8: 80-4.
- Arancibia C., Galgani Y., Valderas J. P., Morales M., Santos J. L., Pollak F. Evaluation of serum insulin levels after an oral glucose load for the diagnosis of insulin resistance. Rev. Med. Chil. 2014; 142 (9): 1106-12.
- Aubert G., Mansuy V., Voirol M. J., Pellerin L, Pralong F. P. The anorexigenic effects of metformin involve increase in hypothalamic leptin expression. Metabolism. 2011; 60 (3): 327-34.
- Bonza C., Lopez-Cuadrado T., Gutierrez-Torres L. F., Amate J. Efficacy and safety of metformin for treatment of overweight and obesity in adolescents: an updated systematic review and meta-analysis. Obes. Facts. 2012; 5 (5): 753-65.
- da Silva R. C., Miranda W. L., Chacra A. R., Dib S. A. Insulin resistanct, beta-cell function, and glucose tolerance in Brazilian adolescents with obesity or risk factors for type 2 diabetes mellitus. J. Diabetes Complications.2007; 21 (2): 84-2.
- Diabetes Prevention Program Research Group. Reduction in the incidence of tipe 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002; 346 (6): 393-403.
- Eriksson J., Lindstrom J., Valle T. Prevention of tipe 2 diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Diabetologia. 1999; 42: 793-801.
- Gandhi P., Bustani R., Madhuvrata P., Farrell T. Introduction of metformin for gestational diabetes mellitus in clinical practice: Has it had an impact? Eur. J. Odstet. Gynecol. Reprod. Biol. 2012; 160 (2): 147-50.
- Gaqnon J., Sheppard E., Anini Y. Metformin directly inhibits ghrelin secretion through AMP - activated protein Kinase in rat primary gastric cells. Diabetes Obes. Metab. 2013; 15 (3): 276-9.
- Khattab S., Mohsen I. A., Aboul Foutuoh I., Ashmawi H. S., Mohsen M. N., van Wely M., van der Veen F., Youssef M. A. Can metformin reduce the incidence of gestational diabetes mellitus in pregnant women with polycystic ovary syndrome? Prospective cohort study. Gynecol. Endocrinol. 2011; 27 (10): 789-93.
- Kurzthaler D., Hadziomerovic-Pekic D., Wildt L., Seeber B. E. Metformin induces a prompt decrease in LH - stimulated testosterone response in women with PCOS independent of its insulin-sensitizing effects. Reprod. Biol. Endocrinol.2014; 12 (1): 98.
- Ijaz H., Vaarasmaki M., Morin-Papunen L., Keravuo R., Ebeling T. Metformin should be considered in the treatment of gestational diabetes: A prospective randomized study. BJOG.2011; 118: 882-5.
- Mallin S. K., Kashyap S. R. Effect of metformin on weight loss: potential mechanisms. Curr. Opin. Endocrinol. Diabetes. Obes. 2014; 21 (5): 323-9.
- Mallin S. K., Finnegan S., Filion J., Rocco M. B., Kirwan J. P. B-cell dysfunction is associated with metabolic syndrome severity in adults. Metab. Syndr. Relat. Disord. 2014; 12 (2): 79-85.
- Metzger B., Oats J., Coustan D., Hod M. Results of the HAPO study: progress towards a new paradigm for detection and diagnosis of GDM. 5th International symposium on Diabetes and pregnancy. Sorrento; 2009: 640.
- Metformin before and during pregnancy and lactation in polycystic ovary syndrome. Expert. Opin. Drug. Saf. 2007; 6 (2): 191-8.
- Mohsen I. A., Elkattan E., Nabil H., Khattab S. Effect of metformin treatment on endometrial vascular indices in anovulatory obese/overweight women with polycystic ovarian syndrome using three-dimensional power Doppler ultrasonography. J. Clin. Ultrasound. 2013; 41 (5): 275-82.
- Nestler J. E. Sex hormone-binding globulin: a marker for hyperinsulinemia and/or insulin resistance? J. Clin. Endocrinol. Metab. 1993; 76: 273-4.
- Petersen J. L., McGuire D. K. Impaired glucose tolerance and impaired fasting glucose - a review of diagnosis, clinical implication and management. Diab. Vasc. Dis. Res. 2005; 2 (1): 9-15.
- Qin K. N., Rosenfield R. L. Role of cytochrome P450c17 in polycystic ovary syndrome. Mol. Cell Endocrinol. 1998; 145 (1-2): 111-21.
- Walsh J. M., Murphy D. J. Weight and pregnancy. BMJ.2007; 335: 169.
- Xinghua Xu, Chigany Du, Qingmei Zheny, Lina Peng, Yuanynan Sun. Effect of metformin on serum Interleikin-6 levels in polycystic ovary syndrome: a systemic review. BMC Womens Health. 2014; 14: 93.
Supplementary files
